For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

Triptolide inhibits IL-12/IL-23 expression in APCs via CCAAT/enhancer-binding protein alpha.

TitleTriptolide inhibits IL-12/IL-23 expression in APCs via CCAAT/enhancer-binding protein alpha.
Publication TypeJournal Article
Year of Publication2010
AuthorsZhang Y, Ma X
JournalJ Immunol
Volume184
Issue7
Pagination3866-77
Date Published2010 Apr 01
ISSN1550-6606
KeywordsAnimals, Antigen-Presenting Cells, CCAAT-Enhancer-Binding Protein-alpha, Diterpenes, Electrophoretic Mobility Shift Assay, Enzyme-Linked Immunosorbent Assay, Epoxy Compounds, Gene Expression, Humans, Immunodominant Epitopes, Immunosuppressive Agents, Interleukin-12, Interleukin-23, Mice, Mice, Knockout, Oligonucleotide Array Sequence Analysis, Peptide Fragments, Phenanthrenes, Promoter Regions, Genetic, Reverse Transcriptase Polymerase Chain Reaction, Transfection
Abstract

Triptolide is a biologically active component purified from Chinese herbal plant Tripterygium wilfordii Hook F. It is widely used in East Asia for treatment of systemic lupus erythematosus, rheumatoid arthritis, nephritis, Bechect's disease, psoriasis, atopic dermatitis, and asthma. However, its immunological mechanisms are poorly understood. IL-12 and IL-23 are closely related heterodimeric cytokines that share the common subunit p40. They are produced by APCs and are key factors in the generation and effector functions of Th1 and Th17 cells, respectively. They have been strongly implicated in the pathogenesis of several autoimmune disorders. In this study, we investigated the molecular mechanism whereby triptolide inhibits the expression of the p40 gene in APCs. We demonstrate that triptolide does so at the transcriptional level in part through targeting CCAAT/enhancer-binding protein-alpha (C/EBPalpha), which directly interacts with the p40 promoter and inhibits its transcription in inflammatory macrophages. Triptolide can activate the transcription of C/EBPalpha, and phosphorylation of Ser21 and Thr222/226 critical for C/EBPalpha inhibition of p40. Further, activation of C/EBPalpha by triptolide is dependent on upstream kinases ERK1/2 and Akt-GSK3beta. This study provides mechanistic insights into the immunomodulatory capacity of triptolide and has strong implications for its therapeutic applications in autoimmune diseases.

DOI10.4049/jimmunol.0903417
Alternate JournalJ Immunol
PubMed ID20194724
PubMed Central IDPMC2965075
Grant ListR21 AT004349-02 / AT / NCCIH NIH HHS / United States
R01 CA100223 / CA / NCI NIH HHS / United States
R21 AT004349-01 / AT / NCCIH NIH HHS / United States
R01 CA100223-01A1 / CA / NCI NIH HHS / United States
R21 AT004349 / AT / NCCIH NIH HHS / United States

Weill Cornell Medicine Microbiology and Immunology 1300 York Avenue, Box 62 New York, NY 10065 Phone: (212) 746-6505 Fax: (212) 746-8587